The combined effects of erlotinib and investigational HDAC inhibitor, scriptaid, increased H3K9 acetylation and could overcome erlotinib resistance and re-sensitize glioblastoma cells to EGFR inhibition [95]. This evidence concerns the gene EGFR and glioblastoma.